The Dermatology Digest

DECEMBER 15, 2023

They reviewed the available safety data and analyzed the risk of 11 adverse events from 14 RCTs published between 2019 and 2022. The post Review Study Aims to Refine Safety Profile of JAK Inhibitors in AD appeared first on The Dermatology Digest.

Safety 36

Safety Dermatitis Dermatology Management 36

The Dermatology Digest

DECEMBER 20, 2023

Tim Raducha-Grace Named Chief Platform Officer at Zerigo Health Tim Raducha-Grace is the new Chief Platform Officer at Zerigo Health, a connected phototherapy platform that couples a handheld Narrow-band ultraviolet B (NB-UVB) light device with a smartphone app and team of care providers to allow patients to treat psoriasis and eczema at home.

Dermatology 36

Dermatology Surgery Eczema Office 36

The Dermatology Digest

JANUARY 30, 2024

The Pediatric Dermatology Research Alliance (PeDRA) has awarded nearly $240K to support pediatric dermatology research across four competitive grant programs. The post And the Winners Are…PeDRA Announces 2023 Grant Recipients appeared first on The Dermatology Digest.

Partnerships 36

Partnerships Eczema Hospital Dermatology 36

The Dermatology Digest

DECEMBER 15, 2023

“The approval of Adbry for pediatric patients living with moderate-to-severe atopic dermatitis expands the therapeutic options for those living with this disease who historically have had a limited selection to choose from,” says Julie Block, President and CEO of the National Eczema Association, in a news release.

Eczema 36

Eczema Dermatitis Safety Therapy 36

The Dermatology Digest

DECEMBER 15, 2023

“The approval of Adbry for pediatric patients living with moderate-to-severe atopic dermatitis expands the therapeutic options for those living with this disease who historically have had a limited selection to choose from,” says Julie Block, President and CEO of the National Eczema Association, in a news release.

Eczema 36

Eczema Dermatitis Safety Therapy 36

The Dermatology Digest

MAY 16, 2024

Emma Guttman-Yassky, MD, PhD , the Waldman Professor and Chair of Dermatology at Icahn Mount Sinai and the Mount Sinai Health System in New York City, has been awarded a new $6.6 NIH Grant to Study Dupilumab in Pediatric AA appeared first on The Dermatology Digest. PHOTO CREDIT: DermNet The post Mount Sinai Awarded $6.6M

Eczema 69

Eczema Dermatitis Safety Innovations 69

The Dermatology Digest

FEBRUARY 14, 2024

The regulatory submissions of nemolizumab in prurigo nodularis are based on data from the phase III OLYMPIA clinical trial program, which evaluated the efficacy and safety of nemolizumab administered subcutaneously every four weeks in patients with prurigo nodularis.

Dermatitis 78

Dermatitis Clinic Safety Dermatology 78

The Dermatology Digest

MARCH 10, 2024

More than two-thirds of people with atopic dermatitis (AD) and darker skin tones treated with lebrikizumab showed improvements in skin clearance and itch relief, according to late-breaking results from a Phase 3 study are being presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting in San Diego.

Skin Types 36

Skin Types Fitzpatrick Scale Dermatitis Safety 36

The Dermatology Digest

JANUARY 14, 2024

The overwhelming majority of people with atopic dermatitis (AD) treated with investigational roflumilast cream 0.15% (Zoryve, Arcutis) showed a measurable improvement in Eczema Area and Severity Index (EASI) in 4 weeks, according to new pooled analyses from two Phase 3 studies. Fully 91.5%

Dermatitis 36

Dermatitis Safety Dermatology Hospital 36

Renee Rouleau

MARCH 10, 2023

Take Vaseline, for instance—Vaseline is petroleum jelly, a petroleum-derived product, and it’s considered so safe that it’s even recommended by the National Eczema Foundation. The bottom line is that synthetic fragrances are extremely pure and predictable since they’re made in a lab, so their safety is well understood.

Skincare 195

Skincare Irritation Ingredients Sensitive Skin 195

The Dermatology Digest

JANUARY 11, 2024

of atopic dermatitis (AD) patients using Vtama (tapinarof) cream, 1% achieved Eczema Area and Severity Index (EASI )75 in an integrated analysis of all the ADORING Program studies, Dermavant reports. Storrs Medical Dermatology Professor and Director of CLEAR Eczema Center, at the Oregon Health & Science University, in a news release.

Dermatitis 36

Dermatitis Safety Eczema Sensitive Skin 36

The Dermatology Digest

DECEMBER 15, 2023

“The approval of Adbry for pediatric patients living with moderate-to-severe atopic dermatitis expands the therapeutic options for those living with this disease who historically have had a limited selection to choose from,” says Julie Block, President and CEO of the National Eczema Association, in a news release.

Eczema 28

Eczema Dermatitis Safety Therapy 28

The Dermatology Digest

JANUARY 23, 2024

The research was presented by Jonathan I Silverberg, MD, Associate Professor of Dermatology and Director of Clinical Research and Contact Dermatitis at The George Washington University School of Medicine in Washington, DC, during the late breaker session at Maui Derm 2024. Safety was assessed throughout the study.

Dermatitis 36

Dermatitis Safety Sustainability Eczema 36

The Dermatology Digest

JANUARY 16, 2024

and Sanofi), adding efficacy and safety data for people aged 12 years and older with atopic dermatitis (AD) and uncontrolled moderate-to-severe hand and/or foot involvement. The post Label Update: FDA Green Lights Dupilumab for AD Patients With Moderate-to-Severe Hand and Foot Involvement appeared first on The Dermatology Digest.

Dermatitis 36

Dermatitis Pharmaceutical Safety Eczema 36

The Dermatology Digest

APRIL 22, 2024

Adult atopic dermatitis (AD) patients previously treated with dupilumab (Dupixent, Regeneron and Sanofi) who received 400mg eblasakimab weekly achieved Eczema Area Severity Index (EASI) 90, and 66.7% Treatment was well-tolerated and no new safety signals were identified.

Pharmaceutical 36

Pharmaceutical Dermatitis Eczema Injections 36

The Dermatology Digest

MARCH 11, 2024

No new safety signals were observed in this trial. The Eczema Area and Severity Index (EASI)-75 score was also maintained in 76% of those receiving nemolizumab—both Q4W and Q8W—compared to 64% receiving a placebo.

Dermatitis 36

Dermatitis Safety Dermatology Eczema 36

The Dermatology Digest

MARCH 11, 2024

These are the main findings from part 2 of a phase 2b trial that was presented at the 2024 annual meeting of the American Academy of Dermatology in San Diego, CA. The post Sanofi’s OX40-ligand Blocker Produces High Durable Response Rates in AD With Quarterly Dosing appeared first on The Dermatology Digest.

Sustainability 36

Sustainability Dermatitis Safety Hospital 36

The Dermatology Digest

FEBRUARY 14, 2024

VTAMA cream also demonstrated highly statistically significant improvement in the proportion of patients with ≥75% improvement in the Eczema Area and Severity Index (EASI75) from baseline to Week 8 compared to patients on vehicle, a key secondary endpoint in the pivotal trials.

Dermatitis 74

Dermatitis Office Management Eczema 74

First Derm

FEBRUARY 21, 2024

Social media significantly influences the popularity of retinol among young people, leading to increased experimentation without considering safety. However, there are concerns about the safety of using retinol on younger skin due to the physiological differences between children’s and adults’ skin.

Retinol 104

Retinol Social Media Skincare Routine Skincare 104

US Dermatologt Partners

MARCH 27, 2024

Dermatology Partners in Cedar Park, Texas , “ Red light therapy is so new that the dermatologic community hasn’t even settled on one name for it. Improves psoriasis , rosacea , acne , and eczema side effects. Safety and Side Effects This procedure is considered safe. According to Dr. Jean Charles of U.S.

Therapy 41

Therapy Treatments Dermatology Safety 41

The Dermatology Digest

JULY 25, 2024

The trials evaluated the efficacy and safety of nemolizumab in combination with background topical corticosteroids (TCS), with or without topical calcineurin inhibitors (TCI), versus placebo in combination with TCS, with or without TCI, in adolescent and adult patients with moderate-to-severe AD.

Dermatitis 36

Dermatitis Safety Eczema Clinic 36

The Dermatology Digest

DECEMBER 21, 2023

This was first reported by study co-author Stuart Turvey, MBBS, DPHIL, FRCPC in 2017 in patients with an immune dysregulatory and hypereosinophilic syndrome characterized by severe eczema and asthma. New Research Highlights Tissue-Specific Roles of JAK Signaling appeared first on The Dermatology Digest.

Dermatitis 36

Dermatitis Eczema Safety Dermatology 36

Eminence Organics

OCTOBER 31, 2023

Lavender oil is known to lessen redness and irritation caused by dry skin and eczema. Robinson says: “Heat and steam are known triggers for many dermatologic conditions, such as rosacea, melasma and eczema.” Pro tip: If you don’t have herbs or oils available, adding a couple of tea bags can help achieve the same results.

Facials 73

Facials Sebum Hydration Moisturization 73

Eminence Organics

OCTOBER 31, 2023

Lavender oil is known to lessen redness and irritation caused by dry skin and eczema. Robinson says: “Heat and steam are known triggers for many dermatologic conditions, such as rosacea, melasma and eczema.” Pro tip: If you don’t have herbs or oils available, adding a couple of tea bags can help achieve the same results.

Facials 70

Facials Sebum Hydration Moisturization 70

The Dermatology Digest

AUGUST 4, 2023

Richard, MD, Assistant Professor, Johns Hopkins Dermatology, Baltimore, Maryland “Why do I like phototherapy? These guidelines generally apply across all disease states, ranging from the big 3 in Dr. Richard’s practice—psoriasis, eczema, and vitiligo—to a whole host of other diagnoses, she said. J Dermatolog Treat. Elisabeth G.

Eczema 36

Eczema Private Practice Therapy Dermatitis 36

The Dermatology Digest

OCTOBER 5, 2023

“It all boils down to stress,” said Keira Barr, MD, who presented “Beauty & The Beast: Stress, Trauma, Skin Disease & A Somatic Approach to Healing,” during the “Mind Body Therapies as Treatment Strategy in Dermatology: What is the Evidence?” This [can trigger] or exacerbate conditions like psoriasis, acne, and eczema.

Safety 36

Safety Social Media Therapy Sun Protection 36

The Dermatology Digest

DECEMBER 18, 2023

The new AD guidelines also: • Highlight the safety of the topical calcineurin inhibitors with typical usage once or twice daily. The Joint Task Force is a partnership between the American College of Allergy, Asthma, and Immunology (ACAAI) and the American Academy of Allergy, Asthma and Immunology. Suggest against elimination diets for AD.

Dermatitis 36

Dermatitis Partnerships Therapy Safety 36

US Dermatologt Partners

JANUARY 24, 2024

Dermatology Partners in McKinney, Texas , “When people talk about psoriasis , they typically focus on the thickened skin plaques, the flakiness, dryness, itching, pain, and irritation associated with flare-ups of this condition. Dermatology Partners for tailored advice and effective management strategies. Dermatology Partners.

Management 36

Management Skin Health Medical Dermatology 36

The Dermatology Digest

FEBRUARY 9, 2024

Brian Hilberdink, Leo Pharma’s EVP of North America, chatted with TDD about the significance of this study and the deleterious effect that chronic hand eczema can have on a person’s quality of life. Patients living with chronic hand eczema are impacted in their everyday lives and experience social, psychological, and physical effects.

Eczema 36

Eczema Dermatitis Marketing Safety 36

The Dermatology Digest

AUGUST 30, 2024

The approval is based on previously available human safety data and data from a well-controlled animal study in which ACAM2000 vaccine was shown to be effective in protecting against mpox virus exposure. The post FDA OKs Emergent’s mPox Vaccine appeared first on The Dermatology Digest.

Portfolios 73

Portfolios Tools Eczema Safety 73

First Derm

DECEMBER 26, 2023

Skin Conditions (Eczema, Psoriasis, Contact Dermatitis) as Causes of Dry, Itchy Scalp Various skin conditions can lead to a dry, itchy scalp: a. Eczema (Dermatitis): Symptoms : Red, itchy, scaly patches on the scalp. 7] Triggers and Aggravators Common for Eczema and Psoriasis : Stress, hormonal changes, and environmental factors.

Management 64

Management Dermatitis Eczema Consultation 64

The Dermatology Digest

MAY 6, 2024

The Phase 2a trial ( NCT05984784 ) evaluates the safety, pharmacokinetics, and efficacy of IMG-007 in adult patients with moderate-to-severe AD who had inadequate response to and/or intolerant of topical therapies. Key study endpoints include safety and percent change from baseline in eczema area and severity index (EASI) over time.

Safety 36

Safety Dermatitis Therapy Dermatology 36

The Dermatology Digest

MARCH 7, 2024

The drug demonstrated significant and clinically relevant improvements in itch, patient-assessed quality-of-life indicators, inflammation, and safety, with minimal side effects and strong patient tolerability when compared to baseline.

Safety 36

Safety Dermatitis Eczema Clinic 36

The Dermatology Digest

DECEMBER 19, 2023

The primary endpoint of the clinical trial was safety and tolerability. Statistical significance was achieved for improvement in patient-reported eczema severity; the clinically relevant threshold of improvement by 4 or more points was met in six patients (75%).

Dermatitis 36

Dermatitis Eczema Clinic Therapy 36

The Dermatology Digest

DECEMBER 14, 2023

The National Eczema Association (NEA) announced the recipients for its 2023 research grants. The 2023 research grantees include: The Champion Research Grant encourages researchers to continue research on emerging or ongoing challenges in eczema or bring their expertise to the field of eczema.

Eczema 36

Eczema Dermatitis Hospital Networking 36

The Dermatology Digest

JANUARY 8, 2024

Kimball, MD, MPH, a professor of Dermatology at Harvard Medical School and the President and CEO of Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center in Boston, in a news release. The post HS Pipeline Watch: Abbvie’s Lutikizumab Advances to Phase 3 in HS appeared first on The Dermatology Digest.

Medical 36

Medical Clinic Therapy Eczema 36

The Eco Well Blog

MAY 8, 2023

She is also an adjunct professor in the Department of Dermatology at the Keck School of Medicine of the University of Southern California. Her area of clinical expertise is in complex medical dermatology, skin cancer, and acne. Carl presented at the Sunscreen E-Summit on behalf of DSM.

Legal 52

Legal Technology Sun Protection Branding 52